We are an emerging leader with new solutions in the field of nuclear medicine technology

BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”).

– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy – BELOIT, Wis.

– Positive RadioGenix System market momentum continues – – Increasing weekly domestic production of non-uranium based Mo-99 – Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m) patient doses are dispensed using RadioGenix Systems and non-uranium molybdenum-99 (Mo-99) NorthStar recognized by U.S.